Innovent Biologics Inc.
IVBXF | OTC
$9.90
-$1.40 (-12.39%)
At close: Oct 30, 2026, 2:35 PM ET
$9.90
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Market Data
Market Cap $17.26B
Enterprise Value $99.45B
Beta 0.24
Average Volume 2.17K
Shares Outstanding (Diluted) 1.8B
Shares Change YoY 10.98%
Institutional Ownership N/A
Exchange OTC
ISIN KYG4818G1010
Price Performance
Price Change 1M -21.0%
Price Change 3M -7.8%
Price Change 6M -12.0%
Price Change YTD 1.5%
Price Change 1Y -7.0%
Price Change 3Y 68.1%
Price Change 5Y 7.8%
1M CAGR (ann.) -19.9%
1Y CAGR (ann.) -11.1%
5Y CAGR (ann.) -3.6%
All-Time CAGR 17.4%
Valuation
PE Ratio 103.32
Forward PE 30.33
PEG Ratio 15.98
Forward PEG 0.78
PS Ratio 7.74
Forward PS 4.80
PB Ratio 5.65
P/FCF Ratio 12.80
P/Adj. FCF Ratio 13.34
P/OCF Ratio 8.91
EV/Sales 6.38
EV/EBIT 53.09
EV/EBITDA 37.86
EV/FCF 10.54
Earnings Yield 1.0%
FCF Yield 8.2%
Adj. FCF Yield 7.9%
Financial Health
Net Cash ¥17.7B
Total Debt ¥2.32B
Cash & Short-Term Investments ¥20B
Total Assets ¥41.61B
Current Ratio 2.68
Quick Ratio 2.48
Debt / Equity Ratio 0.11
Debt / EBITDA 0.88
Debt / FCF 0.25
OCF / Debt 4.16
Interest Coverage 32.09
Altman Z-Score 4.48
Piotroski F-Score 8
Margins & Profitability
Gross Profit Margin 81.0%
Operating Profit Margin 12.0%
EBITDA Margin 16.3%
Net Profit Margin 7.8%
FCF Margin 60.5%
Adj. FCF Margin 58.0%
SBC / Revenue 2.5%
SBC Impact (per share) -4.1%
Returns
Return on Assets 2.9%
Return on Equity 6.1%
Return on Invested Capital 4.5%
Return on Capital Employed 5.8%
Return on Tangible Assets 3.0%
Historical Growth (CAGR)
Revenue CAGR 3Y 109.9%
Revenue CAGR 5Y 295.7%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 191.5%
EPS CAGR 5Y 64.9%
EPS CAGR 10Y N/A
FCF CAGR 3Y 320.3%
FCF CAGR 5Y 326.9%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Hold
Analyst Count 0
EPS Growth Next 3Y 86.3%
Revenue Growth Next 3Y 31.4%
Earnings Date Mar 31, 2027
EPS Estimate (next Q) $0.03
EPS Growth Est (next Q) -11750.4%
Revenue Est (next Q) $240.57M
Revenue Growth Est (next Q) 57.8%
Fair Value Estimates
Graham Number $1.98
Graham Upside -80.0%
Lynch Fair Value $2.40
Lynch Upside -75.8%
Price Target $0.00
Price Target Upside N/A
Cash Flow
Operating Cash Flow ¥9.66B
Free Cash Flow ¥9.43B
Adj. Free Cash Flow ¥9.05B
FCF Per Share $7.53
OCF Per Share $7.77
OCF/S Ratio 86.0%
Income Statement
Revenue ¥15.59B
Gross Profit ¥12.62B
Operating Income ¥1.87B
EBITDA ¥2.63B
Net Income ¥1.22B
EPS (Diluted) $0.67
Revenue / Employee $2.08M
Profit / Employee $161.97K
Employees 7,502
Add to Watchlist
Select watchlists to add or remove IVBXF